KP Tissue Releases Third Quarter 2026 Financial Results

Kruger Products delivered strong Q3 growth, but its new TAD facility faces further delays.

What the company is saying

KP Tissue Inc. is highlighting robust financial performance at Kruger Products for Q3 2026, with revenue up 5.1% to $589.7 million and Adjusted EBITDA rising 9.1% to $93.5 million year-over-year. The company frames the narrative around sustained profitable growth, emphasizing over three consecutive years of improvement and strong sales in both Canada and the U.S. CEO Dino Bianco attributes the gains to higher sales volumes, favorable pricing, and effective brand investment, while acknowledging an uncertain economic environment. The announcement is candid about escalating input costs and inflationary pressures, stating that productivity initiatives and pricing adjustments are under consideration. The company is transparent about the delay in its new TAD facility project, citing deferred location decisions due to economic and trade uncertainty, and now expects the facility will not commence operations in 2028. A quarterly dividend of $0.21 per share is declared, reinforcing a message of ongoing shareholder returns.

What the data suggests

Kruger Products’ Q3 2026 revenue of $589.7 million represents a $28.6 million increase over Q3 2025, driven by higher Consumer segment volumes and improved U.S. pricing. Adjusted EBITDA rose to $93.5 million, up $7.8 million or 9.1%, reflecting margin expansion as cost of sales and SG&A grew at slower rates than revenue. Net income nearly doubled year-over-year to $27.7 million, supported by higher EBITDA, foreign exchange gains, and lower interest expense, partially offset by higher taxes and depreciation. Liquidity remains strong at $434.2 million as of September 30, 2026. KPT’s own Q3 net income was $3.1 million, with $3.3 million from its share of Kruger Products’ earnings. The dividend of $0.21 per share is consistent with prior payouts. The company’s balance sheet shows $176.4 million in cash, $332.6 million in inventories, and $1.42 billion in property, plant, and equipment. While operational results are strong, the TAD facility project is now officially delayed, with no operations expected in 2028, and no updated capex or milestone details provided. The Q4 2026 outlook is for slightly lower Adjusted EBITDA than Q3, but still above Q4 2025, assuming tariffs remain stable.

Analysis

The announcement's tone is positive but proportionate to the strong, realised financial results: revenue, Adjusted EBITDA, and net income all show clear year-over-year growth, and these are supported by detailed numerical disclosures. The only forward-looking claims relate to the delayed TAD facility project and a modest Q4 2026 EBITDA outlook, both of which are presented with appropriate caution and do not overstate near-term benefits. The capital intensity flag is set due to the ongoing TAD facility project, but the company is transparent about delays and does not exaggerate its impact. There is no evidence of narrative inflation or overstatement; the language is factual and supported by the disclosed data. The majority of claims are realised, and the forward-looking ratio is low. The gap between narrative and evidence is minimal.

Risk flags

• ●Escalating input costs and inflationary pressures pose a direct threat to future margins, as acknowledged by management, and may require further pricing or productivity actions to maintain profitability.
• ●The new TAD facility project faces significant execution risk, with the final location decision deferred and operations not expected to begin in 2028, introducing uncertainty around future capacity expansion and capital allocation.
• ●Exposure to foreign exchange fluctuations and higher freight and warehousing costs, as seen in Q3, could continue to impact cost of sales and erode margin gains if not effectively managed.

Bottom line

Kruger Products delivered a strong Q3, with revenue, Adjusted EBITDA, and net income all showing solid year-over-year growth and margin improvement. Liquidity is robust, and the dividend payout continues, providing near-term returns to shareholders. However, the indefinite delay of the new TAD facility pushes any capacity-driven growth or related returns well into the future, with no clear timeline for resolution. The company is transparent about cost pressures and is considering mitigation strategies, but ongoing inflation and FX volatility remain risks. Investors should focus on the sustainability of current margin gains and monitor for more concrete updates on the TAD project. The most important takeaway is that while core operations are performing well, long-term growth from new capacity is now on hold.

Announcement summary

(TSX:KPT) KP Tissue Inc. reported its Q3 2026 financial and operational results, including those of Kruger Products Inc., in which KPT holds a 12.0% interest. Kruger Products' revenue for Q3 2026 was $589.7 million, up from $561.1 million in Q3 2025, representing an increase of $28.6 million or 5.1%. Adjusted EBITDA for Kruger Products was $93.5 million in Q3 2026 compared to $85.7 million in Q3 2025, an increase of 9.1%. Net income for Kruger Products was $27.7 million in Q3 2026, up from $14.6 million in Q3 2025, an increase of $13.1 million. The Board of Directors of KPT declared a quarterly dividend of $0.21 per share, payable on January 15, 2027 to shareholders of record at the close of business on December 31, 2026. Cost of sales for Kruger Products was $481.1 million in Q3 2026 compared to $460.0 million in Q3 2025, an increase of $21.1 million or 4.6%. Selling, general and administrative expenses were $48.8 million in Q3 2026 versus $47.9 million in Q3 2025, an increase of $0.9 million or 1.9%. As of September 30, 2026, Kruger Products' total liquidity, including cash and availability under revolving credit agreements, was $434.2 million. KPT reported net income of $3.1 million in Q3 2026, which included $3.3 million as its share of Kruger Products' net income, a dilution gain of $0.1 million, and depreciation expense of $0.3 million related to acquisition adjustments. Kruger Products had cash and cash equivalents of $176,407 thousand and restricted cash of $30,150 thousand as of September 30, 2026. Trade and other receivables were $165,728 thousand, inventories were $332,643 thousand, and prepaid expenses were $12,488 thousand as of September 30, 2026. Property, plant and equipment totaled $1,421,174 thousand, right-of-use assets were $182,958 thousand, and goodwill was $152,021 thousand as of September 30, 2026. Current liabilities included trade and other payables of $367,033 thousand and dividends payable of $15,345 thousand. Kruger Products operates ten FSC® COC-certified production facilities in North America and employs approximately 3,000 people. The company continues to make progress on its new TAD facility project, but a final location decision is deferred due to economic and trade uncertainty, and the facility is now anticipated to be delayed and not commence operations in 2028. For Q4 2026, assuming a similar tariff environment, Kruger Products expects Adjusted EBITDA to be slightly below Q3 2026 but above Q4 2025. The company held its third quarter conference call on November 11, 2026, and presentation materials were made available online.

Disagree with this article?